Selinexor for higher-risk smoldering myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial studies selinexor, a medicine taken by mouth, to slow or treat intermediate- or high-risk smoldering multiple myeloma before it becomes symptomatic. It may help some people reduce disease progression, based on how well the treatment controls the abnormal plasma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have smoldering multiple myeloma confirmed by blood and bone marrow tests, and you do not currently have organ-damage symptoms (no CRAB criteria)
- Your myeloma is considered intermediate or high-risk based on specific lab or scan measures (such as M-protein level, bone marrow plasma cell percentage, or light-chain ratio)
- Your liver, kidneys, and blood counts are within acceptable ranges for treatment
- You can swallow tablets and you are able and willing to follow study visits and instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This Phase 2 trial tests selinexor (a targeted anti-cancer medicine) plus low-dose dexamethasone to treat multiple myeloma that has not responded to many prior treatments. It compares selinexor combinations depending on what medicines you’ve already had, aiming to reduce myeloma activity and improve outcomes.
This study tests a new combination of drugs for people with multiple myeloma that has stopped responding to previous treatments. The goal is to see if adding selinexor to other anti-myeloma drugs can help control the disease.
This trial tests a three-drug combination (selinexor, ruxolitinib, and methylprednisolone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
Hear when a new Smoldering Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.